Liquidia Corporation

LQDA

Healthcare|Medical - Pharmaceuticals|US

$44.40

-0.09 (-0.20%)

Tangible Book / Share

$2.12

Graham Number

$8.78

Cash / Share

$3.20

Clinical Trials (11)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT07759804 A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag	Pulmonary Arterial Hypertension (PAH)	P4	Recruiting	20	Open-label	—
NCT03992755 Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil	Primary Pulmonary Hypertension	P3	Active	92	Open-label	LIQ861 Inhaled Treprostinil
NCT04691154 A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD	Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases	P3	Active	28	Open-label	—
NCT07285655 A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD	Pulmonary Hypertension Due to Lung Disease (Disorder)	P3	Recruiting	344	RCT, Double-blind	L606, Placebo
NCT07561034 The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease	Pulmonary Hypertension, Interstitial Lung Disease	N/A	Recruiting	30	RCT, Single-blind	—
NCT06129240 An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH	Pulmonary Hypertension, Interstitial Lung Disease		Active	80	—	LIQ861
NCT03399604 Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil	Primary Pulmonary Hypertension	P3	Completed	121	Open-label	LIQ861 Inhaled Treprostinil
NCT01224262 A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001	Influenza	P1P2	Completed	152	RCT, Double-blind	Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine), LIQ001 (0.45mg), LIQ001 (1.8mg)
NCT03884465 Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil	Pulmonary Arterial Hypertension	P2	Terminated	15	Open-label	Inhaled dry powder treprostinil (LIQ861)
NCT07748000 A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks	Raynaud's Phenomenon Secondary to Systemic Sclerosis	P2	Not Yet Recruiting	75	RCT, Open-label	—
NCT02982889 Single Ascending Dose Study of Two Liquidia Bupivacaine Formulations	Acute Pain	P1	Completed	29	RCT, Double-blind	LIQ865A bupivacaine formulation, LIQ865B bupivacaine formulation, Diluent for LIQ865, 0.5% bupivacaine hydrochoride